Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. (Nasdaq: TENX) is a development-stage pharmaceutical company developing therapies for cardiopulmonary diseases. Its prioritized candidate is oral levosimendan, being evaluated in two Phase 3 trials for pulmonary hypertension associated with heart failure with preserved ejection fraction… From the company’s description.
In fiscal 2025, Tenax Therapeutics, Inc. reported a net loss of $52.60M. Operations used $35.80M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Tenax Therapeutics, Inc. does
In the company’s own words
Tenax Therapeutics, Inc. (Nasdaq: TENX) is a development-stage pharmaceutical company developing therapies for cardiopulmonary diseases. Its prioritized candidate is oral levosimendan, being evaluated in two Phase 3 trials for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), a condition with no approved therapies. The company also has TNX-201, a modified-release formulation of imatinib under development for pulmonary arterial hypertension, although its Phase 3 program is currently deprioritized. Levosimendan is approved in many countries for acute decompensated heart failure, while imatinib is approved for other indications, including chronic myeloid leukemia. Tenax licenses levosimendan rights from Orion Corporation and contracts with third parties to manufacture its drug candidates and conduct clinical studies. It operates as a single development-stage pharmaceutical business, with no reportable segments described. As of December 31, 2025, Tenax had 14 full-time and two part-time employees. The company was renamed Tenax Therapeutics in 2014 as it began focusing on levosimendan. Its website is www.tenaxthera.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- CHAPEL HILL, NC
- Fiscal year end
- December
- CIK
- 34956
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Tenax Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Tenax Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Tenax Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Tenax Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Tenax Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”